Baidu
map

Eur J Neurol:女性血浆尿酸水平与卒中风险不相关

2016-04-17 MedSci MedSci原创

背景:血浆尿酸水平升高与总卒中风险增加是否相关的结果不一致;并且,有关女性的研究较少。研究者对女性血浆尿酸浓度和缺血性卒中之间的相关性进行了检测,并评估主要心血管危险因素的效应修饰。方法:一个按照年龄,种族,吸烟状况,绝经状态,绝经后激素治疗配对的嵌套病例对照设计,受试者为护士健康研究的女性参与者,受试者在1989年到1990年提供血样,收集抽血日期和空腹状态。储存的血液样本检测血浆尿酸。1990

背景:血浆尿酸水平升高与总卒中风险增加是否相关的结果不一致;并且,有关女性的研究较少。研究者对女性血浆尿酸浓度和缺血性卒中之间的相关性进行了检测,并评估主要心血管危险因素的效应修饰。

方法:一个按照年龄,种族,吸烟状况,绝经状态,绝经后激素治疗配对的嵌套病例对照设计,受试者为护士健康研究的女性参与者,受试者在1989年到1990年提供血样,收集抽血日期和空腹状态。储存的血液样本检测血浆尿酸。1990到2006,利用国家调查的卒中标准,从医疗记录确认460例缺血性卒中发生。应用多变量条件逻辑回归模型进行了估计。

结果:在匹配的分析中,血浆尿酸每增加1mg/dl,缺血性卒中的风险增加了15% [ 95%CI 3% -28%],但校正心血管疾病的危险因素后,尤其是高血压史后,这种相关性不显著。在配对研究中,尿酸的最高四分位数与缺血性卒中风险增加显著相关(RR 1.56;95% CI 1.06-2.29,但校正心血管疾病的危险因素后,这种相关性不再显著(RR 1.43;95% CI 0.93-2.18)。未观察到主要心血管危险因素存在显著效应修饰。

结论:女性血浆尿酸水平与缺血性卒中风险增加并不独立相关。血尿酸与脑卒中危险因素相关,但与卒中风险无关。

原文出处:

Jiménez MC, Curhan GC, et al. Plasma uric acid concentrations and risk of ischaemic stroke in women. Eur J Neurol. 2016 Apr 9.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2017-03-31 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-19 李继凯

    文章高大上

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-18 1de9282dm20(暂无匿称)

    跟我们的研究不谋而合??

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-18 kingjiang

    不相关,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-18 lyh994

    能不能从机制上深入研究?

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1999679, encodeId=b6cc19996e947, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 31 10:31:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281210, encodeId=de66128121035, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Apr 19 09:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79511, encodeId=a762e95117b, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:24:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79313, encodeId=6818e9313c3, content=跟我们的研究不谋而合??, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19711706499, createdName=1de9282dm20(暂无匿称), createdTime=Mon Apr 18 09:31:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79296, encodeId=4aa6e9296a4, content=不相关,, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erJaiboOUVrGYoHV8Essd0EJvx0DPLDeqP3qkvaGD39DdvMmzT98iaib209rApLicEN84Nu8RefibOh8jA/132, createdBy=75ba1609552, createdName=kingjiang, createdTime=Mon Apr 18 07:00:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79289, encodeId=4ee4e9289f8, content=能不能从机制上深入研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Apr 18 00:17:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79276, encodeId=ae97e92762d, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 21:28:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 dhzzm

    学习了,很好

    0

相关资讯

Sci Rep:尿酸能增强树突状细胞瘤苗的抗肿瘤活性

来自四川大学的魏于全院士课题组人员证实,尿酸能够增强树突状细胞瘤苗的抗肿瘤免疫。这一重要的研究发现发布在11月10日的《Scientific Reports》杂志上。 近年来,肿瘤的免疫治疗备受关注,其已成为继肿瘤手术治疗、放疗、化疗后第四种治疗放啊。树突状细胞(DC)是机体内功能最强的抗原提呈细胞(APC),也是唯一能够刺激初始免疫应答的APC,在对肿瘤产生主动免疫上起着重要的作用:它摄取、加

Medicine :低血清尿酸与卒中后抑郁相关

卒中后抑郁(PSD)是卒中常见的并发症,并与卒中患者不良预后相关。这篇研究旨在探索PSD患者和血清尿酸的相关性。研究者招募了196了急性缺血性患者和100个健康自愿者。应用尿酸酶PAP法检测入院24 小时血清尿酸水平。卒中后3个月评估患者神经心理学。应用17项汉密尔顿抑郁量表评估抑郁症状。PSD的诊断与DSM-IV抑郁诊断标准一致。应用多变量logistic回归模型进行分析。共有56(28.6%)

Lancet子刊:血浆尿酸浓度和冠心病风险:孟德尔随机分析

循环系统中血浆尿酸浓度增加与冠心病风险增加相关,但尿酸对冠心病风险影响的病因学仍旧不清晰。最新在2016年1月15日,在线发表于Lancet Diabetes Endocrinol杂志上的一项研究,使用孟德尔随机分析对尿酸在冠心病风险方面的病因学进行了阐明。研究首先采用固定效应荟萃分析观察血浆尿酸和冠心病风险的关系,然后使用传统孟德尔随机方法,基于31尿酸相关单核苷酸多肽(SNPs)遗传工具探究相

FDA批准阿斯利康痛风药物Lesinurad治疗痛风相关高尿酸血症

FDA批准阿斯利康痛风药物 Lesinurad(Zurampic) (200mg/d)与黄嘌呤氧化酶抑制剂 (XOI)一起用于治疗痛风相关高尿酸血症。Lesinurad 可尿酸的排泄,减少其生成。控制高尿酸血症是痛风长期治疗的重中之重,Zurampic为数百万一生中可能出现痛风的人群提供了一种新的治疗选择。痛风表现为突然发生的关节剧烈疼痛和肿胀,最常见于大脚趾。在美国有160万名痛风患者,其中85

重磅炸弹!FDA委员会通过了用于痛风治疗的新药——lesinurad

FDA委员会通过了用于痛风治疗的新药——lesinurad 近日,FDA委员会以10:4的结果通过了lesinurad(200 mg/d)用于治疗痛风相关的高尿酸血症,可联合黄嘌呤氧化酶抑制剂(XOLs)共同用药。Sean Bohen博士,全球药物开发执行副总裁和首席医疗官,认为委员会推荐lesinurad用于痛风的治疗是个令人激动的进步。他期待这能为痛风的治疗提供一种新的治疗方法:当与黄嘌呤氧化

BMJ:左外踝巨大渗出性包块病例报道

61岁精神分裂症男性,以发烧、疲劳、腿部疼痛和行走困难为主要表现。在他的腿和手肘有质硬包块,最大的位于左外踝(直径14cm),且有开放性创口,持续渗出。X线:病变区域有软组织包块和多个钙化灶。渗出物含有针状晶体,该物质见于痛风石。患者最初的尿酸值为494 µmol/L。患者停止服用治疗高尿酸血症的药物:苯溴马隆和柠檬酸钾;开始口服别嘌呤醇、栓剂双氯芬酸、静注盐酸头孢替安。原始出处:Tomohiko

Baidu
map
Baidu
map
Baidu
map